BCP-T.A. is a ferroptosis inducer.
1 It induces ferroptosis in NCI H522 non-small cell lung cancer (NSCLC) cells (IC
50 = 17 nM), an effect that can be blocked by the ferroptosis inhibitor liproxstatin-1 . BCP-T.A. binds to glutathione peroxidase (GPX4) and increases the accumulation of lipid peroxides in NCI H522 cells when used at a concentration of 0.5 μM. It is cytotoxic to WI38 human lung fibroblasts and mouse embryonic fibroblasts (MEFs; IC
50s = 22 and 10 nM, respectively), as well as NCI H522, HT-1080 fibrosarcoma, MDA-MB-468 and MDA-MB-231 breast, and HeLa cervical cancer cells (IC
50s = 17, 19, 84, 21, and 242 nM, respectively).